Alzheimer Dementia, Statins
Conditions
Brief summary
Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.
Interventions
DRUGSTA 4783
Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
Sponsors
Region Stockholm
Karolinska Institutet
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients with AD and mixed dementia registered in SveDem and from SCREAM.
Exclusion criteria
* All patients with a missing MMSE score at diagnosis date will be excluded from the analyses. * Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive decline | Through study completion, at least 1 year | The data on cognitive change will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome. |
Countries
Sweden
Outcome results
None listed